AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview

 
• By Sarah Karlin-Smith
  
exit painted on pavement.
A negative 21 November advisory committee recommendation could portend a marketing exit for Andexxa. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Product Reviews